Plato Investment Management Ltd Raises Holdings in AbbVie Inc. $ABBV

Plato Investment Management Ltd raised its position in AbbVie Inc. (NYSE:ABBV) by 9.1% during the second quarter, according to its most recent filing with the SEC. The institutional investor owned 61,586 shares of the company’s stock after purchasing an additional 5,154 shares during the period. AbbVie accounts for approximately 0.9% of Plato Investment Management Ltd’s portfolio, making the stock its 18th biggest holding. Plato Investment Management Ltd’s holdings in AbbVie were worth $15,407,000 at the end of the most recent quarter.

Other institutional investors and hedge funds also recently added to or reduced their stakes in the company. Bell Investment Advisors Inc grew its holdings in shares of AbbVie by 5.6% during the second quarter. Bell Investment Advisors Inc now owns 3,761 shares of the company’s stock worth $946,000 after buying an additional 198 shares in the last quarter. Hexagon Capital Partners LLC lifted its stake in shares of AbbVie by 18.3% in the second quarter. Hexagon Capital Partners LLC now owns 8,314 shares of the company’s stock worth $2,092,000 after buying an additional 1,289 shares in the last quarter. Idaho Trust Co acquired a new position in AbbVie during the second quarter worth about $233,000. Compass Capital Management Inc. purchased a new stake in AbbVie during the 2nd quarter valued at about $201,000. Finally, Prospect Financial Group LLC grew its stake in AbbVie by 6.0% during the 2nd quarter. Prospect Financial Group LLC now owns 1,139 shares of the company’s stock valued at $287,000 after acquiring an additional 64 shares in the last quarter. Institutional investors and hedge funds own 70.23% of the company’s stock.

Insiders Place Their Bets

In other AbbVie news, EVP Nicholas Donoghoe sold 32,710 shares of the business’s stock in a transaction that occurred on Friday, August 14th. The stock was sold at an average price of $250.00, for a total value of $8,177,500.00. Following the sale, the executive vice president owned 74,430 shares of the company’s stock, valued at $18,607,500. The trade was a 30.53% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Company insiders own 0.06% of the company’s stock.

AbbVie Stock Down 1.8%

ABBV stock opened at $258.23 on Friday. The stock has a market cap of $456.24 billion, a price-to-earnings ratio of 72.95, a price-to-earnings-growth ratio of 0.87 and a beta of 0.30. AbbVie Inc. has a 52-week low of $190.75 and a 52-week high of $267.47. The business has a fifty day moving average of $251.87 and a two-hundred day moving average of $228.68.

AbbVie (NYSE:ABBV) last issued its quarterly earnings data on Friday, July 31st. The company reported $3.65 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $3.61 by $0.04. AbbVie had a negative return on equity of 422.07% and a net margin of 9.80%.The firm had revenue of $16.99 billion during the quarter, compared to the consensus estimate of $16.80 billion. During the same period last year, the company earned $2.97 EPS. The company’s quarterly revenue was up 10.2% on a year-over-year basis. AbbVie has set its Q3 2026 guidance at 3.840-3.880 EPS. As a group, sell-side analysts anticipate that AbbVie Inc. will post 14.06 EPS for the current year.

AbbVie Dividend Announcement

The business also recently disclosed a quarterly dividend, which was paid on Friday, August 14th. Investors of record on Wednesday, July 15th were given a dividend of $1.73 per share. The ex-dividend date of this dividend was Wednesday, July 15th. This represents a $6.92 dividend on an annualized basis and a dividend yield of 2.7%. AbbVie’s dividend payout ratio (DPR) is presently 195.48%.

Trending Headlines about AbbVie

Here are the key news stories impacting AbbVie this week:

• Positive Sentiment: AbbVie submitted an application to the European Medicines Agency for subcutaneous induction of SKYRIZI in adults with moderately to severely active Crohn’s disease. The filing, supported by positive Phase 3 AFFIRM data, could expand SKYRIZI’s European Crohn’s disease label and offer patients a less invasive alternative to intravenous induction. AbbVie Submits Regulatory Application to EMA for SKYRIZI Subcutaneous Induction
• Positive Sentiment: The company’s inclusion in articles highlighting reliable dividend stocks reinforces AbbVie’s appeal to income-focused investors. Its dividend profile and defensive healthcare exposure may provide support, particularly during periods of economic or inflation uncertainty. 3 Dividend Stocks, 12 Paychecks a Year
• Positive Sentiment: Ken Griffin reportedly increased his AbbVie stake by 547% during the second quarter, signaling confidence from a prominent institutional investor in the company’s dividend and long-term prospects. Ken Griffin Increased His Stake in AbbVie
• Neutral Sentiment: AbbVie’s patient-support efforts, including an immunology scholarship program, strengthen its public-facing support initiatives but are unlikely to materially affect near-term earnings or valuation. AbbVie’s Immunology Scholarship Program
• Negative Sentiment: Valuation concerns may be limiting upside. AbbVie has rallied significantly and is trading at a premium, prompting debate over whether future growth from SKYRIZI and the broader pipeline can justify the stock’s price. Has AbbVie Stock Become Too Expensive to Buy?

Analysts Set New Price Targets

A number of research analysts have weighed in on the stock. UBS Group raised their target price on shares of AbbVie from $230.00 to $260.00 and gave the stock a “neutral” rating in a research note on Monday, July 13th. Wells Fargo & Company upped their price target on AbbVie from $295.00 to $300.00 and gave the company an “overweight” rating in a research report on Monday, August 17th. Canaccord Genuity Group lifted their price objective on AbbVie from $282.00 to $290.00 and gave the stock a “buy” rating in a research report on Monday, August 3rd. Barclays boosted their price objective on AbbVie from $275.00 to $300.00 and gave the stock an “overweight” rating in a research note on Wednesday, July 29th. Finally, Citigroup upped their target price on AbbVie from $230.00 to $260.00 and gave the company a “neutral” rating in a report on Wednesday, July 15th. Two research analysts have rated the stock with a Strong Buy rating, nineteen have given a Buy rating and five have assigned a Hold rating to the company. According to data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average target price of $275.95.

AbbVie Company Profile

AbbVie is a global, research-driven biopharmaceutical company that was created as a spin-off from Abbott Laboratories in 2013 and is headquartered in North Chicago, Illinois. The company focuses on discovering, developing and commercializing therapies for complex and often chronic medical conditions. Its operations span research and development, manufacturing, regulatory affairs and commercialization, with an emphasis on bringing specialty medicines to market across multiple therapeutic areas.

AbbVie’s product portfolio and pipeline cover several major therapeutic categories, including immunology, oncology, neuroscience, virology and women’s health.